Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Nivo w/ Ipi OR Ipilimumab Alone in Advd Melanoma Pts Refractory to an Anti-PD-1 or Anti-PD-L1 Agent

Protocol: SWOG-S1616

Full Title

A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent

Skin Cancers Melanoma